Last reviewed · How we verify
Late Glargine
At a glance
| Generic name | Late Glargine |
|---|---|
| Also known as | lantus |
| Sponsor | The Cleveland Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management (PHASE4)
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (PHASE3)
- Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan (NA)
- Characteristics of Glargine in Type 2 Diabetics (PHASE1)
- Late Night Snack and Insulin Glargine (NA)
- Health Care for Type 1 Diabetes in Developing World (NA)
- Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects (PHASE4)
- Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Late Glargine CI brief — competitive landscape report
- Late Glargine updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI